Investor relations
Stay up to date with our fundraising campaigns as well as important project updates impacting existing shareholders.
Why invest in Brainify.AI
Over 40% of depressed patients don’t respond to existing treatments. We are facing a mental health epidemic unprepared. Brainify.AI pioneers precision psychiatry through biomarker identification for personalized antidepressant development and therapy selection.
We address the low success rates of depression clinical trials by leveraging machine learning and deep learning to analyze EEG data. All our patented AI technology has been developed in-house using over 13.5 million training segments and validated on separate clinical trial data.
Merck GHI, Northpond Ventures, McKesson, Kodori Family Office
Current investors
Merck GHI, Northpond Ventures, McKesson, Kodori VC
Psychiatry
Over 40% of depressed patients don’t respond to existing treatments. We are facing a mental health epidemic unprepared. Brainify.AI pioneers precision psychiatry through biomarker identification for personalized antidepressant development and therapy selection.
AI/ML
We address the low success rates of depression clinical trials by leveraging machine learning and deep learning to analyze EEG data. All our patented AI technology has been developed in-house using over 14 million training segments and validated on separate clinical trial data.
Learn more about investment opportunities
I am already an investor
Keep up to date with our latest developments